Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells-Reference-Cited by-同舟云学术

Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells

Published:2024-08-02 Issue: Volume: Page:
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Chokshi Chirayu R.^ORCID,Shaikh Muhammad Vaseem,Brakel Benjamin,Rossotti Martin A.,Tieu David,Maich William,Anand Alisha,Chafe Shawn C.,Zhai Kui,Suk Yujin,Kieliszek Agata M.,Miletic Petar,Mikolajewicz Nicholas^ORCID,Chen David,McNicol Jamie D.,Chan Katherine^ORCID,Tong Amy H. Y.,Kuhlmann Laura,Liu Lina,Alizada Zahra,Mobilio Daniel,Tatari Nazanin,Savage Neil,Aghaei Nikoo,Grewal Shan,Puri Anish,Subapanditha Minomi,McKenna Dillon,Ignatchenko Vladimir,Salamoun Joseph M.,Kwiecien Jacek M.,Wipf Peter^ORCID,Sharlow Elizabeth R.,Provias John P.,Lu Jian-Qiang^ORCID,Lazo John S.^ORCID,Kislinger Thomas^ORCID,Lu Yu,Brown Kevin R.,Venugopal Chitra,Henry Kevin A.,Moffat Jason^ORCID,Singh Sheila K.^ORCID

Funder

Terry Fox Research Institute

Mitacs

Foundation for the National Institutes of Health

Gouvernement du Canada | Canadian Institutes of Health Research

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41591-024-03138-9.pdf

Reference84 articles.

1. DeVita, V. T. Jr. The evolution of therapeutic research in cancer. N. Engl. J. Med. 298, 907–910 (1978).

2. Ostrom, Q. T. et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013. Neuro Oncol. 18, v1–v75 (2016).

3. Lapointe, S., Perry, A. & Butowski, N. A. Primary brain tumours in adults. Lancet 392, 432–446 (2018).

4. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).

5. Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466 (2009).